Figure 2: BCOR expression in CCSKs.
From: Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney
(a) Targeted RT–PCR of a segment of the BCOR transcript (exons 14 and 15) in CCSKs from female patients demonstrated expression of both the wild-type product (491 bp) and a larger product corresponding to the mutant (ITD) allele, confirming expression of the ITD from the active X chromosome. (b) Box-and-whisker plot of estimated BCOR transcript abundance from RNA-seq data in ITD-positive CCSKs (ITD+) demonstrating high expression of BCOR in comparison to an ITD-negative CCSK (ITD−), Wilms tumours (Wilms) and assorted soft-tissue sarcomas (STS). UDS with BCOR–CCNB3 fusions also had upregulated BCOR expression. Bar representing 25th–75th percentile, line representing the maximum and minimum values. (c) Immunoblot using an antibody to full-length BCOR protein10 demonstrated a 192-kDa product corresponding to the predicted size of BCOR10 in ITD-positive CCSK tumours (T) but not in matched normal kidney samples (N). ACTB, beta-actin. (d) Haematoxylin-and-eosin-stained section of CCSK showing classic histologic pattern. Immunohistochemistry with BCOR antibody demonstrated strong nuclear staining in the tumour cells in (e) CCSKs but not in (f) Wilms tumours.
